Enzon is developing Oncaspar-IV to enhance the pharmaceutical properties of the currently available product. Oncaspar-IV utilizes an efficient modern process for manufacturing of L-asparaginase, and an improved PEG linker to enhance stability, said Enzon.
Jeffrey Buchalter, chairman and CEO of Enzon, said: “Today’s announcement is a significant milestone in our overall plan to market the new Oncaspar-IV in new geographic territories. We are currently developing the next-generation Oncaspar product to enhance the pharmaceutical properties of the approved version currently marketed in the US.”